MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock,...
$12,167,852
Proceeds from exercise of
pre-funded warrants
$977
Net cash provided by
financing activities
$12,117,967
Canceled cashflow
$50,862
Net increase
(decrease) in cash and cash...
$4,360,408
Canceled cashflow
$7,757,559
Payment of prior period
issuance costs
$50,495
Payment for fractional
shares in reverse stock...
-$367
Stock-based compensation
$143,732
Prepaid expenses and
other current assets
-$30,470
Accrued and other
current liabilities
$14,852
Net cash used in
operating activities
-$7,757,559
Canceled cashflow
$189,054
Interest income
$215,041
Net loss
-$7,558,557
Accounts payable
-$388,056
Canceled cashflow
$215,041
Total selling,
general and...
$4,843,615
Total research and
development
$2,929,983
Back
Back
Cash Flow
source: myfinsight.com
Dermata Therapeutics, Inc. (DRMAW)
Dermata Therapeutics, Inc. (DRMAW)